Anlon healthcare Limited has received confirmation from both major depositories regarding the new ISIN allocation for its upcoming equity share subdivision. The company had earlier announced the subdivision of its equity shares with a record date of April 24, 2026.

Share Subdivision Details

The company is proceeding with the subdivision of its existing equity shares, converting each share with a face value of Rs. 10 into 5 shares with a face value of Rs. 2 each. The depositories NSDL and CDSL have confirmed the allocation of the new ISIN for the subdivided shares.

Depository Confirmations

Both major depositories have confirmed the activation of the new ISIN. Central Depository Services (India) Limited (CDSL) activated the ISIN INE0Y8W01025 on April 17, 2026. The activation was confirmed through their communication dated April 17, 2026, reference number CDSL/ISS/RB/49404.

National Securities Depository Limited (NSDL) also confirmed the ISIN activation on April 20, 2026, through their communication reference NSDL/II/DR/JNG/1058/2026. NSDL's confirmation included details about the registrar arrangement for the new shares.

Registrar and Implementation

KFIN Technologies Limited, with Registrar ID IN200800, has been designated as the registrar for the new equity shares. The subdivision will take effect under the new ISIN from the record date of April 24, 2026.

The company has informed both BSE Limited (Scrip Code: 544497) and National Stock Exchange of India Limited (Scrip Code: AHCL) about the new ISIN allocation and the upcoming subdivision implementation.

Anlon Healthcare has formally approved the acquisition of a majority stake in Remember India Health Links Private Limited through a board meeting held on April 16, 2026. The pharmaceutical company's board of directors unanimously approved this strategic acquisition to expand its operations and transform its business model.

Board Meeting Outcomes and Regulatory Disclosure

The board meeting, conducted at the company's registered office from 12:30 p.m. to 01:00 p.m. IST, approved the acquisition of 1,11,00,000 equity shares representing 63.98% of Remember India Health Links' equity share capital. The company has entered into a share purchase agreement dated April 16, 2026, with Remember India Health Links and its majority shareholders for this acquisition.

The company has made the necessary disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to both BSE and NSE exchanges.

Target Company Profile and Financial Performance

Remember India Health Links Private Limited, incorporated on December 17, 2020, operates in the pharmaceutical manufacturing sector. The company specializes in manufacturing, processing, and dealing in pharmaceutical finished products including tablets and capsules.

Strategic Transformation Objectives

The acquisition represents a significant strategic shift for Anlon Healthcare, enabling transformation from an API manufacturer to a complete pharmaceutical provider. Through this acquisition, the company will expand across the pharmaceutical value chain by moving into finished dosage formulations while gaining access to more than 30 dossiers relating to finished dosage formulations.

The impact of the proposed acquisition is expected to extend across operational, financial and regulatory dimensions, facilitating integration of quality control processes, strengthening the financial profile, and enhancing market positioning from a B2B ingredient supplier to a broader pharmaceutical platform.

Transaction Structure and Timeline

The acquisition will be completed through cash consideration as specified in the share purchase agreement. The transaction is subject to completion of certain condition precedents and is expected to be completed within 4 to 5 months from the signing date. Upon completion, Remember India Health Links will become a subsidiary of Anlon Healthcare, providing the company with majority control and enhanced operational capabilities in the pharmaceutical sector.